Direct-From-Specimen Pneumonia Test Detects Pathogens and Resistance in Hours

By LabMedica International staff writers
Posted on 19 Nov 2026

Pneumonia is a leading cause of sepsis and is associated with high mortality. Conventional culture-based pathogen identification and antimicrobial susceptibility testing can take two to four days, delaying information needed to guide antibiotic treatment. A new direct-from-specimen bacterial identification and susceptibility testing panel is now being evaluated in U.S. clinical microbiology laboratories to deliver results within hours.

Pattern Bioscience’s Pneumonia ID/AST Panel is being evaluated at five clinical microbiology laboratories across the United States through the company’s Early Evaluation Program. The panel is designed to support pneumonia diagnosis by identifying the organism causing infection and determining which antibiotics are likely to be effective. It provides bacterial detection, pathogen identification, and antimicrobial susceptibility testing in a single assay performed directly from lower respiratory tract specimens.


Image: The assay runs on Pattern’s single-cell microbiology platform, a rapid phenotypic testing system designed for direct-from-specimen analysis (Photo courtesy of Pattern Bioscience)

The assay runs on Pattern’s single-cell microbiology platform, a rapid phenotypic testing system designed for direct-from-specimen analysis. The platform is intended to deliver results within hours rather than the days typically required by conventional culture-based methods. Through the Early Evaluation Program, laboratory directors, medical laboratory scientists, and clinical partners can gain hands-on experience with the system in their own laboratories while providing feedback on workflow, integration pathways, and usability.

The Pneumonia ID/AST Panel has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). Subject to FDA clearance, Pattern plans to introduce the Pneumonia ID/AST Panel as its first commercial product.

“We appreciate the partnership of our early evaluation sites. Through these collaborations, we will continue to learn how laboratories will integrate the Pattern system into their routine workflow, and we will generate additional data to help quantify the potential impact of the platform,” said Carey-Ann Burnham, PhD, Chief Executive Officer.

Related Links
Pattern Bioscience


Latest Microbiology News